OMB APPROVAL
OMB NUMBER: 3235-0145
UNITED STATES EXPIRES: DECEMBER 31, 2005
SECURITIES AND EXCHANGE COMMISSION ESTIMATED AVERAGE BURDEN
WASHINGTON, D.C. 20549 HOURS PER FORM.............15
SCHEDULE 13D
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. )*
IMAGE TECHNOLOGY LABORATORIES, INC.
(Name of Issuer)
COMMON STOCK, PAR VALUE $0.01 PER SHARE
------------------ ----------------------------------------
(Title of Class of Securities)
45247A 10 5
(CUSIP Number)
JAMES QUINLAN, 500 N. WESTSHORE BLVD., SUITE 1010, TAMPA , FLORIDA 33069
PHONE: (813) 289-1020
(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications)
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition that is the subject of this Schedule 13D, and is filing this
schedule because of ss.ss.240.13d-l(e), 240.13d-l(f) Or 240.13d-l(g), check the
following box. [ ]
NOTE: Schedules filed in paper format shall include a signed original and five
copies of the schedule, including all exhibits. See ss.240.13d-7 for other
parties to whom copies are to be sent.
The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class
of securities, and for any subsequent amendment containing information
which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not
be deemed to be "filed" for the purpose of Section 18 of the Securities
Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of
that section of the Act but shall be subject to all other provisions of
the Act (however, see the Notes).
PERSONS WHO RESPOND TO THE COLLECTION OF INFORMATION CONTAINED IN THIS FORM ARE
NOT REQUIRED TO RESPOND UNLESS THE FORM DISPLAYS A CURRENTLY VALID OMB CONTROL
NUMBER.
CUSIP NO. 45247A 10 5
------------------- ------------------------------------------------------------
1
NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Valerie McDowell
------------------- ------------------------------------------------------------
2
CHECK THE APPROPRIATE BOX IF MEMBER OF A GROUP* (a)
(b)
------------------- ------------------------------------------------------------
3
SEC USE ONLY
------------------- ------------------------------------------------------------
4
SOURCE OF FUNDS*
OO
------------------- ------------------------------------------------------------
5
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURUANT TO ITEMS 2(d) or 2(e)
------------------- ------------------------------------------------------------
6
CITIZENSHIP OR PLACE OF ORGANIZATION
United States
------------------- -------- ---------------------------------------------------
7
SOLE VOTING POWER
NUMBER OF
SHARES 4,688,584
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
------------------- -------- ---------------------------------------------------
8
SHARED VOTING POWER
------------------- -------- ---------------------------------------------------
9
SOLE DISPOSITIVE POWER
4,688,584
------------------- -------- ---------------------------------------------------
10
SHARED DISPOSITIVE POWER
------------------- ------------------------------------------------------------
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
4,688,584
------------------- ------------------------------------------------------------
12
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES*
------------------- ------------------------------------------------------------
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
30.5%
------------------- ------------------------------------------------------------
14
TYPE OF REPORTING PERSON*
IN
------------------- ------------------------------------------------------------
ITEM 1. SECURITY AND ISSUER
This statement relates to the common stock, par value $.01 per share
(the "Common Stock"), of Image Technology Laboratories, Inc., a Delaware
corporation (the "Company"). The Company's principal executive offices are
located at 602 Enterprise Drive, Kingston, New York 12401.
ITEM 2. IDENTITY AND BACKGROUND
Valerie McDowell (the "Reporting Individual") is the widow of Dr.
David Ryon, President and Chief Executive Officer of the Company until his death
on December 8, 2004. During the last five years, the Reporting Individual has
not been convicted in a criminal proceeding (excluding traffic violations or
similar misdemeanors) nor been a party to a civil proceeding of a judicial or
administrative body of competent jurisdiction resulting in him being subject to
a judgment, decree or final order enjoining future violations of, or prohibiting
or mandating activities subject to, federal or state securities laws or finding
any violations with respect to such laws. The Reporting Individual is a United
States citizen.
ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION
At the time of Dr. Ryon's death, the Reporting Individual held 88,000
shares of the Company's Common Stock. As a result of Dr. Ryon's death, as his
surviving spouse, the Reporting Individual received an additional 3,603,504
shares of the Company's Common Stock and options to purchase 1,000,000 shares of
Common Stock at an exercise price of $.25 per share (the "Options").
ITEM 4. PURPOSE OF TRANSACTION
The Reporting Individual is holding the shares of Common Stock and
the Options for investment. The Reporting Individual may, from time to time,
make additional purchases of shares of Common Stock and may dispose of any or
all of the shares of Common Stock or the common stock underlying the Options
held by her at any time.
The Reporting Individual has no plans or proposals which relate to,
or could result in, any of the matters referred to in paragraphs (a) through (j)
of Item 4 of Schedule 13D. The Reporting Individual may review or reconsider her
position with respect to the Company or to the formulation of plans or proposals
with respect to any such matter, but has no present intention of doing so.
ITEM 5. INTEREST IN SECURITIES OF THE ISSUER
According to information available to the Reporting Individual in
publicly filed materials, the number of shares of Common Stock outstanding as of
March 21, 2005 was 14,388,788. Accordingly, as of the date hereof, the Reporting
individual is the beneficial owner of 3,688,584 shares of Common Stock and
Options to purchase 1,000,000 shares of Common Stock, or 30.5% of the
outstanding Common Stock, calculated in accordance with Rule 13d-3(d)(1). The
reporting Individual will have sole voting and dispositive power with respect to
these 4,688,584 shares.
No other purchases were effected by the Reporting Individual during
the past sixty days.
ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT
TO SECURITIES OF THE ISSUER.
There are no contracts, arrangements, understandings or relationships
(legal or otherwise) between the Reporting Individual and any other person with
respect to any securities of the Company, including, but not limited to,
transfer or voting of any of the securities underlying the Options, finders
fees, joint ventures, loan or option arrangements, puts or calls, guarantees of
profits, division of profits or loss, or the withholding of proxies.
ITEM 7. MATERIAL TO BE FILED AS EXHIBITS
None
After reasonable inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.
Dated: June 10, 2005
Reporting Individual:
/s/ Valerie McDowell
--------------------
VALERIE MCDOWELL